There is no antidote to ELIQUIS. Overdose of ELIQUIS increases the risk of bleeding [see WARNINGS AND PRECAUTIONS].

In controlled clinical trials, orally administered apixaban in healthy subjects at doses up to 50 mg daily for 3 to 7 days (25 mg twice-daily for 7 days or 50 mg once-daily for 3 days) had no clinically relevant adverse effects.

In healthy subjects, administration of activated charcoal 2 and 6 hours after ingestion of a 20-mg dose of apixaban reduced mean apixaban AUC by 50% and 27%, respectively. Mean apparent half-life of apixaban decreased from 13.4 hours when apixaban was administered alone to 5.3 hours and 4.9 hours, respectively, when activated charcoal was administered 2 and 6 hours after apixaban, indicating that charcoal blocked the continued absorption of apixaban from the gut [see CLINICAL PHARMACOLOGY]. Thus, administration of activated charcoal may be useful in the management of apixaban overdose or accidental ingestion by leading to a more rapid fall in apixaban blood levels.

ELIQUIS is contraindicated in patients with the following conditions:

• Active pathological bleeding [see WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS]
• Severe hypersensitivity reaction to ELIQUIS (i.e., anaphylactic reactions) [see ADVERSE REACTIONS]

Last reviewed on RxList: 1/10/2013
This monograph has been modified to include the generic and brand name in many instances.